Compare RCUS & AZZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RCUS | AZZ |
|---|---|---|
| Founded | 2015 | 1956 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Industrial Specialties |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.1B | 3.0B |
| IPO Year | 2018 | N/A |
| Metric | RCUS | AZZ |
|---|---|---|
| Price | $21.31 | $107.38 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 8 | 6 |
| Target Price | $29.38 | ★ $116.33 |
| AVG Volume (30 Days) | ★ 2.1M | 197.5K |
| Earning Date | 10-28-2025 | 01-07-2026 |
| Dividend Yield | N/A | ★ 0.75% |
| EPS Growth | N/A | ★ 855.67 |
| EPS | N/A | ★ 10.37 |
| Revenue | $240,000,000.00 | ★ $1,594,766,000.00 |
| Revenue This Year | N/A | $5.21 |
| Revenue Next Year | N/A | $5.18 |
| P/E Ratio | ★ N/A | $10.34 |
| Revenue Growth | N/A | ★ 1.55 |
| 52 Week Low | $6.50 | $70.90 |
| 52 Week High | $26.40 | $119.95 |
| Indicator | RCUS | AZZ |
|---|---|---|
| Relative Strength Index (RSI) | 41.72 | 58.16 |
| Support Level | $20.35 | $104.00 |
| Resistance Level | $26.10 | $111.49 |
| Average True Range (ATR) | 1.48 | 2.60 |
| MACD | -0.61 | 0.39 |
| Stochastic Oscillator | 15.21 | 58.37 |
Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of cancer. The company focuses on an ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule immuno-oncology product candidates. Its product pipeline includes Domvanalimab, Etrumadenant, AB598, Casdatifan among others. Arcus conducts clinical trials for different types of cancers such as Lung, Colorectal, Pancreatic, and others. The company operates through a single segment which is the business of developing and commercializing immunotherapies.
AZZ Inc is a provider of galvanizing and a variety of metal coating solutions and coil coating solutions to a broad range of end markets in North America. The company's operating segment consists of Metal Coatings, Precoat Metals, and Infrastructure Solutions. The company generates the majority of its revenue from the Precoat Metals segment, which provides coil coating application of protective and decorative coatings and related value-added downstream processing for steel and aluminum coils. Geographically, the company generates the majority of its revenue from the United States.